138 related articles for article (PubMed ID: 21769080)
1. Molecular signatures and prognosis of hepatocellular carcinoma.
Hoshida Y
Minerva Gastroenterol Dietol; 2011 Sep; 57(3):311-22. PubMed ID: 21769080
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis.
Yamazaki K; Masugi Y; Sakamoto M
Dig Dis; 2011; 29(3):284-8. PubMed ID: 21829019
[TBL] [Abstract][Full Text] [Related]
3. The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma.
Ikeguchi M; Iwamoto A; Taniguchi K; Katano K; Hirooka Y
J Exp Clin Cancer Res; 2005 Sep; 24(3):415-21. PubMed ID: 16270528
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-alpha inhibits the intrinsic pathway of c-Myc-induced apoptosis through activation of nuclear factor-kappaB in murine hepatocellular carcinomas.
Cavin LG; Wang F; Factor VM; Kaur S; Venkatraman M; Thorgeirsson SS; Arsura M
Mol Cancer Res; 2005 Jul; 3(7):403-12. PubMed ID: 16046551
[TBL] [Abstract][Full Text] [Related]
5. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter.
Sohn BH; Park IY; Lee JJ; Yang SJ; Jang YJ; Park KC; Kim DJ; Lee DC; Sohn HA; Kim TW; Yoo HS; Choi JY; Bae YS; Yeom YI
Gastroenterology; 2010 May; 138(5):1898-908. PubMed ID: 20038433
[TBL] [Abstract][Full Text] [Related]
6. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease.
Calvisi DF; Pinna F; Ladu S; Pellegrino R; Muroni MR; Simile MM; Frau M; Tomasi ML; De Miglio MR; Seddaiu MA; Daino L; Sanna V; Feo F; Pascale RM
Carcinogenesis; 2008 Aug; 29(8):1639-47. PubMed ID: 18579559
[TBL] [Abstract][Full Text] [Related]
7. [Comparative genomic classification of human hepatocellular carcinoma].
Kaposi-Novák P
Magy Onkol; 2009 Mar; 53(1):61-7. PubMed ID: 19318328
[TBL] [Abstract][Full Text] [Related]
8. Specific molecular markers in hepatocellular carcinoma.
Yao DF; Dong ZZ; Yao M
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):241-7. PubMed ID: 17548245
[TBL] [Abstract][Full Text] [Related]
9. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
[TBL] [Abstract][Full Text] [Related]
10. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
11. Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4.
Zekri AR; Bahnassy AA; Abdel-Wahab SA; Khafagy MM; Loutfy SA; Radwan H; Shaarawy SM
J Gastroenterol Hepatol; 2009 Mar; 24(3):416-28. PubMed ID: 19054267
[TBL] [Abstract][Full Text] [Related]
12. Pathways and gene expression profiles in hepatocellular carcinoma.
Facciorusso A; Nacchiero MC; Rosania R; Laonigro G; Giorgio F; Del Prete V; Panella C; Ierardi E
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):35-48. PubMed ID: 22419003
[TBL] [Abstract][Full Text] [Related]
13. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
Frau M; Biasi F; Feo F; Pascale RM
Mol Aspects Med; 2010 Apr; 31(2):179-93. PubMed ID: 20176048
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population.
Tang SH; Yang DH; Huang W; Zhou HK; Lu XH; Ye G
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4171-7. PubMed ID: 16857788
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.
Daveau M; Scotte M; François A; Coulouarn C; Ros G; Tallet Y; Hiron M; Hellot MF; Salier JP
Mol Carcinog; 2003 Mar; 36(3):130-41. PubMed ID: 12619035
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
Pan HW; Ou YH; Peng SY; Liu SH; Lai PL; Lee PH; Sheu JC; Chen CL; Hsu HC
Cancer; 2003 Jul; 98(1):119-27. PubMed ID: 12833464
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis.
Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Qiyong L; Fujii T; Sugimoto H; Takeda S; Nakao A
Ann Surg Oncol; 2010 Mar; 17(3):923-32. PubMed ID: 19898900
[TBL] [Abstract][Full Text] [Related]
18. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation.
Huang LR; Hsu HC
Cancer Res; 1995 Oct; 55(20):4717-21. PubMed ID: 7553654
[TBL] [Abstract][Full Text] [Related]
19. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].
Xue KX
Ai Zheng; 2005 Jun; 24(6):757-68. PubMed ID: 15946497
[TBL] [Abstract][Full Text] [Related]
20. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma.
Cheng J; Xie HY; Xu X; Wu J; Wei X; Su R; Zhang W; Lv Z; Zheng S; Zhou L
Cancer Lett; 2011 Nov; 310(1):35-45. PubMed ID: 21763068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
